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Abstract
Ensuring the virological safety of biologicals is challenging due to the risk of viral contamination of raw materials and cell
banks, and exposure during in-process handling to known and/or emerging viral pathogens. Viruses may contaminate raw
materials and biologicals intended for human or veterinary use and remain undetected until appropriate testing measures
are employed. The outbreak and expansive spread of the mosquito-borne flavivirus Zika virus (ZIKV) poses challenges to
screening human- and animal -derived products used in the manufacture of biologicals. Here, we report the results of an in
vitro study where detector cell lines were challenged with African and Asian lineages of ZIKV. We demonstrate that this
pathogen is robustly detectable by in vitro assay, thereby providing assurance of detection of ZIKV, and in turn underpinning
the robustness of in vitro virology assays in safety testing of biologicals.
INTRODUCTION
The risk of contamination cell lines and raw materials from
emerging viruses is of great importance in the production of
biopharmaceuticals. Globalization is not limited to the flow
of money, services, goods and people across geographic
boundaries, but also includes the distribution of pathogens
into non-indigenous locations [1]. As a result, in recent dec-
ades the emergence and re-emergence of viruses from one
geographical location to another, or from one susceptible
host to another, has been observed [2–4]. Human immuno-
deficiency virus, severe acute respiratory syndrome corona-
virus, Middle East respiratory syndrome coronavirus,
influenza virus (type A, H1N1), hepatitis A virus, Ebola
virus, West Nile virus (WNV) and Zika virus (ZIKV) are
examples of virus species whose incidence and geographical
spread has increased in the past 20 years and could further
diversify in the near future. The development and manufac-
ture of biologicals and advanced therapy medicinal products
(ATMPs) employs various cell lines, raw materials and
active pharmaceutical ingredients (APIs) [5] from human
and animal sources that require sophisticated safety assays
and Good Manufacturing Practice (GMP) standards. Poten-
tial viral contaminants, including emerging viruses, may
enter biological production processes from cell lines or raw
materials thus posing a risk to downstream applications and
to drug safety. The risk of viral contamination must there-
fore be mitigated by stringent testing at the appropriate
stages of production. Regulatory guidelines and recommen-
dations on viral safety testing outline requirements for test-
ing at various stages of a product life cycle, including raw
materials, cell substrates, virus seeds, unprocessed bulk har-
vests and end products.
ZIKV is an emerging arthropod-borne member of the Flavi-
viridae virus family and is closely related to other mosquito-
borne arboviruses such as dengue virus, yellow fever virus,
WNV and Japanese encephalitis virus [6–9]. The introduc-
tion of ZIKV in the Americas in 2015 [10, 11] highlighted
its epidemic potential and global public health burden [12,
13]. Infection with ZIKV in the majority (~80–90%) of
healthy humans is asymptomatic but it can progress to neu-
rological complications, such as encephalitis, meningo-
encephalitis, Guillain–Barre syndrome in adults and birth
defects, such as fetal and neonatal microcephaly grouped
together as congenital Zika syndrome [14–17]. As of 2016
ZIKV is present in many countries in Africa, Asia and
across the Americas, causing truly global concern. Despite
the identification of ZIKV in 1947 and its reported presence
in Africa and Asia for many decades [18], little attention
has been paid to its potential to contaminate raw products
of human or animal origin used in the manufacture of
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biologicals. In nature, ZIKV circulates through a sylvatic
cycle involving multiple mosquito species (primarily from
the Aedes family) and primates, the natural reservoir species
for ZIKV [19–23] (Fig. 1). The predominant transmission
route of ZIKV to humans occurs via the bite of an infected
mosquito, although non-vector-borne routes of ZIKV trans-
mission have been documented, including sexual transmis-
sion [24–26], blood transfusion [27, 28], organ
transplantation [29] and perinatal transplacental transmis-
sion [30]. Infectious ZIKV particles have been detected in
saliva, blood, serum, semen and urine [25, 28, 31–33] of
infected humans. Indeed, the broad tropism of the virus and
its persistence [17] may lead to longer-term issues in
affected countries. As a result, ZIKV may enter biopharma-
ceutical production in materials from viraemic, yet asymp-
tomatic, donors or from donors with persistent replication
of the virus in the urinary tract or renal system, as the possi-
bility of persistent ZIKV infection in multiple tissues has
recently been demonstrated in a rhesus macaque model
[34]. Therefore, raw material of human origin from affected
areas should be considered as potentially contaminated with
ZIKV including, but not limited to, blood and blood com-
ponents (plasma, platelets, convalescent serum, monocytes,
heterologous T cells, albumins, coagulating factors, immu-
noglobulins) [35] and urine, which serves as a source of
pharmacologically active substances such as human chori-
onic gonadotropin (hCG), human menopausal gonadotro-
pin or menotropin (HMG), follicle-stimulating hormone
(FSH) and urokinase [36–38]. Limited epidemiologic sur-
veillance evidence suggests that ZIKV infection in wider
mammal species [39] may be possible. A study performed
in Indonesia in the late 1970s suggested that horses, cows,
Fig. 1. Transmission of Zika virus (ZIKV) and risk for manufacturing of biologicals and advanced therapy medicinal products. In nature,
ZIKV circulates through a sylvatic cycle involving multiple mosquito species (primarily from the Aedes family) and primates, the reser-
voir species for ZIKV. The predominant transmission route of ZIKV to humans occurs via the bite of an infected mosquito. Infectious
ZIKV particles have been detected in the blood, serum and urine of infected humans. Infection with ZIKV in the majority (~80–90%) of
healthy humans is asymptomatic. As a result, ZIKV may enter biopharmaceutical production in materials from viraemic, yet asymp-
tomatic, donors or from donors with persistent replication of the virus in the urinary tract or renal system. Therefore raw material of
human origin from affected areas should be considered as potentially contaminated with ZIKV including, but not limited to, materials
such as blood fractions (plasma, platelets, and convalescent serum) and urine, which serves as a source of pharmacologically active
substances (human chorionic gonadotropin (hCG), human menopausal gonadotropin or menotropin (HMG), follicle-stimulating hormone
(FSH) and urokinase).
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carabaos (water buffaloes), goats, ducks and bats were sero-
positive for antibodies against ZIKV [21, 40]. This may sug-
gest that raw materials from these species may harbour this
pathogen, but the limited nature of the study and lack of
independent correlation relegates the risk to theoretical.
However, it is worth mentioning that even in monkeys and
apes, which are natural reservoirs of ZIKV, only a few natu-
rally and experimentally infected monkeys and apes have
demonstrated any symptoms or manifested any clinical dis-
ease when infected with ZIKV [21]. Furthermore, recent
reports of ZIKV replication in cell lines such as non-human
primate (Vero and LLC-MK2), pig (PK-15), rabbit (RK-13),
hamster (BHK21) and chicken (DF-1) [41] clearly suggest
that a wide range of animal cell lines relevant to the manu-
facture of biopharmaceuticals may be susceptible to ZIKV.
In line with a report that goats were seropositive for anti-
bodies against ZIKV, there is a theoretical risk of the intro-
duction of ZIKV contamination during pharmaceutical
processes using raw materials of animal origin. This
includes clonal selection of cells lines by cell sorting with
antibodies or antisera from animal species (goats). To miti-
gate the risk of viral contamination, biological materials are
tested by in vitro assays for the detection of adventitious
viruses, using several susceptible detector cell lines where
the classical reports of cytopathic effects (CPE), haemad-
sorption and haemagglutination [42, 43] may be observed.
We have recently demonstrated that Schmallenberg ortho-
bunyavirus, an emerging viral pathogen of cattle and sheep,
is detectable by classical in vitro adventitious virus assays
[44]. ZIKV has been reported to elicit CPE in a panel of
continuous cell lines [45, 46], leading us to suggest that an
in vitro assay utilizing appropriate cells lines with CPE end
point, in a GMP-compliant assay platform, may represent a
suitable means to ensure the robust detection of ZIKV in
biological materials. The Food and Drug Administration
(FDA) [47], European Pharmacopeia (Ph. Eur) [48] and
World Health Organisation (WHO) [49] guidelines for the
qualification of cell substrates and other raw materials used
for the production of biologicals specify that the monolayer
cultures of detector cells include cultures of the same species
and tissue type used for production of the test article, in
addition to cultures of a human diploid cell line and mono-
layer cultures of another cell line of a different species (FDA
requirements specify that a monkey kidney cell line should
be used). Therefore, for the purpose of this study, the
human diploid cell line MRC-5 (ATCC, CCL 171) and sec-
ondary African green monkey kidney cells, Vero (ATCC,
C1008 and ATCC, CCL-81) were challenged with two
strains of ZIKV (MR766 and PE243) as detector cells during
classical in vitro adventitious virus biosafety assay.
RESULTS
Cell lines used in this study were manufactured and thor-
oughly characterized under GMP conditions according to
guidelines of the International Conference on Harmoniza-
tion Topic Q5 (ICH Q5) [50]. The characterization of
MRC-5 and Vero cells includes confirmation of cell line
identity and the assessment of purity and freedom from
fungi and bacteria (sterility), as well as mycoplasma and
adventitious viruses testing.
The human diploid cell line MRC-5 demonstrated cyto-
pathic effects (CPE) when inoculated with 1000, 100, 10 and
1 TCID50 of ZIKV MR766, an African lineage virus (Fig. 1a,
b, Table 1). The structural changes to host cell morphology,
CPE in the form of retarded cell growth and extensive cell
rounding and lysis by ZIKV were clearly observed. Inocula-
tion of MRC-5 with 1000 TCID50 of ZIKV MR766 was
reported in the majority of wells between days 6 and 10 post
inoculation (pi) with the mean appearance of CPE on day 8.
MRC-5 cells demonstrated early signs of CPE following
inoculation with 100 TCID50 ZIKV MR766 at 6 days
post infection (p.i.), and CPE was observed in all wells at
day 14 pi with the mean appearance of CPE at day 10.
When inoculated with 10 TCID50 of ZIKV MR766, CPE
was reported between days 14 and 17 p.i. with the mean
appearance at day 13. Inoculation with 1 TCID50 ZIKV
MR766 reported CPE in 33% of wells on day 14 and in
50% of wells on day 28 (Table 4). The inoculation of the
Brazilian isolate (Asian lineage) ZIKV PE243[51] at levels of
1000, 100, 10 and 1 TCID50 on the MRC-5 detector cell line
elicited CPE in 67, 44–27 and 11% of wells, respectively,
during a 14-day in vitro assay (Table 2, Fig. 3a, b, Table 4).
The mean appearance of CPE for 1000 and 100 TCID50 was
at days 12 and 14 p.i. On day 14, supernatant from MRC-5
was inoculated onto a subconfluent monolayer of MRC-5
and CPE was observed in 67, 75, 42 and 17% of wells,
respectively, at day 28. CPE in Vero C1008 and Vero CCL-
81 cells was similar to that observed on MRC-5 cells and
presented as structural changes to host cell morphology,
retarded cell growth and extensive cell rounding, detach-
ment and lysis. Vero C1008 reported the presence of 1000
and 100 TCID50 of ZIKV MR766 on all occasions at 14 days
in vitro assay. The onset of CPE was observed as early as
3 days p.i. with the mean appearance of CPE on days 5 and
7 for 1000 and 100 TCID50, respectively. ZIKV MR766 at 10
and 1 TCID50 elicited CPE in 67 and 56% of Vero C1008
wells during 14 days of in vitro culture, with the mean
appearance of CPE on days 8 and 9. Vero C1008 detected
the presence of 1000,100, 10 and 1 TCID50 of ZIKV MR766
in each well inoculated on all occasions during the 28-day
in vitro assay (Tables 2 and 4, Fig. 2e, f). Inoculation with
1000 and 100 TCID50 of ZIKV PE243 elicited CPE in Vero
C1008 wells on all occasions during the 14 days of in vitro
assay, with the mean appearance of CPE on day 8. Vero
C1008 detected the presence of 10 and 1 TCID50 of ZIKV
PE243 on 67 and 56% occasions during the 14 days of in
vitro assay, with the mean appearance of CPE for 10
TCID50. reported on day 9. Inoculation with 1000, 100 and
10 TCID50 ZIKV PE243 elicited CPE in Vero C1008 wells
on all occasions during the 28 days of in vitro assay. Inocula-
tion with 1 TCID50 of ZIKV PE243 reported CPE in 83% of
wells on day 28 (Tables 2 and 4, Fig. 3e and f). Vero CCL-
81 detected 1000 and 100 TCID50 of ZIKV MR766 in all
wells inoculated on each occasion, in 94% of wells
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inoculated with 10 TCID50 ZIKV MR766 and in 44% of
wells inoculated with 10 TCID50 in a 14-day in vitro assay
(Tables 3 and 4). The mean appearance of CPE was
reported on day 6 for 1000 TCID50 inoculum, on day 7 for
100 TCID50 and on day 8 for 10 and 1 TCID50. Vero CCL-
81 detected 1000, 100 and 10 TCID50 of ZIKV MR766 in all
wells inoculated on all occasions and in 75% of wells inocu-
lated with 1 TCID50 during a 28-day in vitro assay (Tables 3
and 4, Fig. 2c, d). Inoculation with 1000, 100, 10 TCID50 of
ZIKV PE243 was detected on all occasions in a 14-day in
vitro assay. ZIKV PE243 inoculated at 1 TCID50resulted in
CPE in 39% of inoculated Vero CCL-81 detector cells in a
14-day in vitro assay and in 100% of inoculated cells in a
28-day in vitro assay (Tables 3 and 4, Fig. 3c, d). The mean
appearance of CPE was reported on day 6 for 1000 TCID50
inoculum, on day 7 for 100 TCID50, on day 9 for 10 TCID50
and on day 14 for 1 TCID50. Inoculation of detector cells
with measles virus and bovine parainfluenza virus type 3 at
100 TCID50, representing system suitability controls for
MRC-5 and Vero detector cell lines, respectively, elicited
clear detection on all occasions (n=18) within 6 days
(Table 4).
DISCUSSION
In this study we addressed the use of a classical in vitro assay
with CPE end-point testing for the detection of ZIKV con-
tamination in biologicals. The Ph. Eur, sections 2.6.16 [42]
and 5.2.3 [48] recommend that cell culture testing for
adventitious viral contaminants on viral vaccines for human
use is performed for a minimum of 14 days. Furthermore it
is also recommended that veterinary vaccines are tested for
the presence of adventitious viruses in an in vitro assay with
a minimum of 28 days’ culture (Ph. Eur. Section 5.2.4) [43].
In this study we challenged detector cell lines with ZIKV of
African (MR766) and Asian lineages (PE243) during 14-
and 28-day in vitro assays to assess standard GMP guide-
lines for adventitious virus testing. We report that the gen-
eral in vitro adventitious virus test with a CPE end point, as
Table 1. Microscopic detection of CPE observed on MRC-5 cells challenged with strains of ZIKV
Monolayers of detector cells were incubated with 1000, 100, 10 and 1 TCID50 ZIKV MR766 and ZIKV PE243 and monitored for CPE over a period of
28 days. Data represent viral inoculations performed on 3 separate occasions (runs 1–3) for each dilution (1000, 100, 10 and 1 TCID50) of ZIKV
MR766 and PE243 on MRC-5 cells. On day 14, supernatants from cultures not showing CPE were inoculated onto fresh detector cells (runs 1 and 2).
Data in the table indicate the first day of CPE appearance, median and mean appearance of CPE, standard variation and coefficient of variation. Sta-
tistical outliers were identified and removed from the analysis.
Day of CPE appearance on MRC-5 cells
Run Well ZIKV MR766 ZIKV PE243
1000 TCID50 100 TCID50 10 TCID50 1 TCID50 1000 TCID50 100 TCID50 10 TCID50 1 TCID50
1 1 7 7 10 – 7 10 10 10
2 7 7 14 – 7 10 10 10
3 7 7 17 – 10 10 10 –
4 7 7 17 – 10 10 10 –
5 7 14 17 – 10 20 10 –
6 10 14 17 – 10 20 – –
2 7 10 10 10 10 – 20 – –
8 10 10 10 10 – 20 – –
9 10 10 10 10 – – – –
10 10 14 10 14 – – – –
11 10 14 14 14 – – – –
12 10 14 14 14 – – – –
3 13 3 7 10 N/A 14 10 N/A N/A
14 7 7 14 N/A 14 10 N/A N/A
15 7 7 14 N/A 14 10 N/A N/A
16 10 10 N/A N/A 14 14* N/A N/A
17 10 10 N/A N/A 14 N/A N/A N/A
18 10 10 N/A N/A 14 N/A N/A N/A
Median 9 9 12 ND 12 13 ND ND
Mean 8 10 13 ND 12 14 ND ND
Standard variation 1 1 2 ND 3 4 ND ND
Coefficient of variation (%) 13 15 13 ND 22 29 ND ND
–, No CPE was visible; N/A, non-applicable; ND, not determined.
*Statistical outlier.
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used in GMP-compliant safety testing of biologicals, was
demonstrably suitable for robust and reproducible detection
(100% detection during our study) of single-digit levels of
ZIKV. Many flaviviruses cause haemadsorption and hae-
magglutination with certain types of erythrocytes [52].
Although not addressed in our study, haemadsorption and
haemagglutination end-point tests could serve as suitable
and complementary to the CPE method of detecting ZIKV
following 14- and 28-day in vitro culture. However, where
haemagglutination end-point tests are known to be concen-
tration dependent in vitro [53], clear and unambiguous CPE
offers a robust end point that does not rely on species-
dependent erythrocyte selection.
Diverse phenotypes of ZIKV have been demonstrated [41,
54, 55] where African strains showed a higher infection rate
than Asian strains, and varying yields of virus produced in
human neuronal cell lines were recently reported. In the
context of quality assurance and GMP compliance it is
therefore also important to assess whether strains from
different origins are robustly detectable, and the variation in
susceptibility of detector cell lines must be taken into
account when assessing the presence of ZIKV in biologicals.
We therefore assessed the suitability of two cell lines, the
human diploid MRC-5 and African green monkey Vero cell
line, to detect ZIKV of African and Asian lineage. MRC-5
cells robustly and reproducibly detected single-digit levels of
ZIKV MR766 whereas inoculation with ZIKV PE243 was
detected on some, but not all, occasions. In order to assess
the suitability of Vero cells to detect different lineages of
ZIKV, we tested two subtypes of Vero cells that are cur-
rently in use in GMP testing laboratories. First, Vero
(ATCC CCL-81), which were isolated from an African
green monkey (Chlorocebus sp.) in 1962 and are referred to
as ‘the original Vero cells’ [56]. Second, Vero C1008 (ATCC
CRL-1586), which are a clone of Vero 76 (ATCC CRL-
1587) isolated from Vero CCL-81 in 1968. Vero C1008 cells
exhibit a slower growth rate in comparison to Vero CCL-81
and show some contact inhibition, and are thus suitable for
Table 2. Microscopic detection of cytopathic effect observed on Vero C1008 cell line challenged with ZIKV
Monolayers of detector cells were incubated with 1000, 100, 10 and 1 TCID50 ZIKV MR766 and ZIKV PE243 and monitored for CPE over a period of
28 days. Data represent viral inoculations performed on 3 separate occasions (runs 1–3) for each dilution (1000, 100, 10 and 1 TCID50) of ZIKV
MR766 and PE243 on Vero C1008 cells. On day 14, supernatants from cultures not showing CPE were inoculated onto fresh detector cells (runs 1
and 2). Data in the table indicate the first day of CPE appearance, median and mean appearance of CPE, standard deviation and coefficient of varia-
tion. Statistical outliers were identified and removed from the analysis.
First day of CPE appearance on Vero C1008
Run Well ZIKV MR766 ZIKV PE243
1000 TCID50 100 TCID50 10 TCID50 1 TCID50 1000 TCID50 100 TCID50 10 TCID50 1 TCID50
1 1 3 7 7 7 7 7 7 7
2 3 7 7 7 7 7 7 7
3 3 7 7 7 7 7 7 7
4 3 7 7 7 7 7 7 7
5 3 7 7 7 7 7 7 –
6 3 7 7 7 7 7 24* –
2 7 3 3 3 7 7 3 7 3*
8 3 3 3 7 7 3 7 7
9 3 3 7 7 7 3 7 7
10 7 7 7 7 7 3 7 7
11 7 7 7 20 7 3 7 7
12 7 7 20* 20 7 7* 7 7
3 13 3* 3* 10 – 7 14 14 –
14 7 10 10 – 7 14 14 –
15 7 10 14 – 7 14 14 –
16 7 10 14 – 10 14 14 –
17 7 10 14 – 10 14 14 –
18 7 10 14 – 10 14 14 –
Median 5 7 8 7 8 8 9 7
Mean 5 7 8 9 8 8 9 7
Standard deviation 2 2 3 2 1 5 3 0
Coefficient of variation (%) 33 28 37 24 9 57 35 0
–, No CPE was visible; N/A, non-applicable.
*Statistical outlier.
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the propagation and detection of slowly replicating viruses,
or viruses which may require several rounds of replication
before becoming fit and detectable for replication in cell cul-
ture. In our study Vero CCL-81 and Vero C1008 cells both
indicated the presence of ZIKV strains MR766 and PE243
in a similar manner. At day 14 of the assay, 10 TCID50 of
ZIKV MR766 was detected on 67% of Vero C1008 and
94% of Vero CCL-81 wells, and 10 TCID50 of ZIKV PE243
on 67% of Vero C1009 and 100% Vero CCL-81 wells.
Detection of isolates from African and Asian lineage down
to the level of 10 TCID50 (approximately 6.9 infectious virus
particles) was observed on all occasions in all inoculated
wells for both Vero cell lines at day 28. Inoculation with
only 1 TCID50 (approximately 0.69 infectious virus par-
ticles) was indicated by CPE on 33–44% of wells on day 14
and on 75–100% of wells on day 28 of the assay (Table 4).
Our data show that that when testing for the presence of
ZIKV in biologicals is required, Vero cells detect ZIKV con-
tamination robustly and reproducibly with a suitable level
of sensitivity. We acknowledge that other strains of ZIKV
(e.g. from central Asia – Cambodia and Thailand) may
show varying phenotypes during in vitro culture which may
also depend on the innate competencies of the cell line in
restricting viruses. However for the purposes of this work,
two divergent strains representing the two major lineages
have been selected. Vero cell lines are deficient in the syn-
thesis of interferon alpha and beta (IFN a/b) – host
immune defence molecules aimed at restricting viral replica-
tion, and a wide range of arthropod-borne viruses including
strains of dengue types 1–4, West Nile, Japanese encephali-
tis, Usutu [57, 58] and ZIKV [41] replicate and elicit CPE in
Vero cells. Importantly, due to an ability to support replica-
tion of a wide range of flaviviruses, the Vero CCL-81 line is
also recommended for virus stock production in the EU
Horizon 2020-funded ZIKAlliance consortium [59] and
used by the Public Health England National Collection of
Pathogenic Viruses (NCPV) to generate authenticated
stocks of ZIKV for supply [60].
Fig. 2. Cytopathic effects observed in detector cell lines challenged with ZIKV MR766. Monolayers of detector cells were incubated
with 1000, 100, 10 and 1 TCID50 ZIKV MR766 monitored for CPE over a period of 14 or 28 days. Micrographs shown are representative
of the observations made in detector cell lines following ZIKV MR766 inoculation and days p.i. (dpi) (panels a, b, c, d, e and f). CPE in
the form of retarded cell growth and extensive cell rounding and lysis was observed. Text in each panel indicates the detector cell line
identity and dpi on which the image was recorded. Inset panels show negative control (NC) mock-infected cells. Scale bar is 1000 µm.
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The aim of the present study was to determine whether a
generically validated assay (in vitro adventitious virus assay)
is able to detect ZIKV that might be present in the raw mate-
rials and cell lines used for the production of biologicals. We
demonstrated that this pathogen is robustly detectable by in
vitro assay, thereby providing assurance of detection of ZIKV
and in turn underpinning the robustness of in vitro virology
assays in safety testing of biologicals. Importantly, the matrix
of the product may be inhibitory to virus detection during the
assay and consequently affect the sensitivity of the detection.
Therefore one of the key assessments during biosafety testing
for finished biologicals is to establish the level of effect, if any,
of the test article matrix on a generally validated assay to
detect contaminants. A study known as a Product Specific
Qualification (PSQ) examines and quantitates the effect of
representative batches of a defined production process on the
performance of an assay. Matrices of bulk harvest that may
be ostensibly similar may have quite different behaviour dur-
ing in vitro assay, and PSQs address this. A PSQ is normally
performed before or during phase III clinical development
and is required as a part of the Biologicals Licence
Application.
In summary, we demonstrated the robust detection of ZIKV
using classical in vitro assays for the detection of adventi-
tious viruses with MRC-5 and Vero cells. We demonstrated
robust detection of single digits of ZIKV of African and
Asian lineage on Vero cells in a 28-day classical in vitro
assay with CPE end-point testing. The described study uses
a proactive and evidence-based approach for mitigating the
risk of ZIKV contamination of raw materials, cell lines and
other components used in the manufacture of biologicals.
MATERIALS
Cells and viruses
The human diploid cell line, MRC-5 (CCL 171) and second-
ary African green monkey kidney cells, Vero (C1008 and
Fig. 3. Cytopathic effects observed in detector cell lines challenged with ZIKV PE243. Monolayers of detector cells were incubated
with 1000, 100, 10 and 1 TCID50 ZIKV PE243 and monitored for CPE over a period of 14 or 28 days. Micrographs shown are representa-
tive of the observations made in detector cell lines following ZIKV PE243 inoculation and days p.i. (dpi) (panels a, b, c, d, e and f). CPE
in the form of retarded cell growth and extensive cell rounding and lysis was observed. Text in each panel indicates the detector cell
line identity and dpi on which the image was recorded. Inset panels show negative control (NC) mock-infected cells. Scale bar is
1000µm.
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CCL-81) were obtained from the American Type Culture
Collection (ATCC) and manufactured and thoroughly char-
acterized by BioReliance under GMP conditions according
to guidelines of the International Conference on Harmoni-
zation Topic Q5 (ICH Q5) [50]. The characterization of
MRC-5 and Vero cells includes confirmation of cell line
identity and the assessment of purity and freedom from
fungi and bacteria (sterility), as well as mycoplasma and
adventitious viruses testing. MRC-5 cells (lot number:
04112W, passage 29–31)were cultured in high-glucose Dul-
beco’s modified Eagle’s medium (HG-DMEM, Gibco) sup-
plemented with 10% Foetal Clone III (Hyclone), 2mM L-
glutamine (Gibco) and 1mM non-essential amino acids
(NEAA, Gibco). Vero C1008 (lot number: 040711W, pas-
sage 30–52) and Vero CCL-81 (lot number: 120606, passage
139–150) cells were cultured in HG-DMEM with 10% fetal
bovine serum (FBS, Gibco). For titration and subsequent in
vitro adventitious virus assays, both detector cell lines were
maintained in Eagle’s minimum essential medium (EMEM,
Gibco) supplemented with 2% FBS, 2mM L-glutamine,
1mM sodium pyruvate (Gibco), 100Uml 1 penicillin
(Gibco), 100 µgml 1 streptomycin (Gibco), 2.4 µgml 1
amphotericin B (Sigma) and 50 µgml 1 Gentamicin
(Gibco). Two strains of ZIKV were used for this study, rep-
resenting the African and Asian lineages. The African ZIKV
strain, LC002520/MR766/1947/Uganda (abbreviated as
MR766) was isolated in 1947 from Rhesus monkeys in the
Zika Forest in Uganda. ZIKV MR766 was obtained from
BEI Resources, NIAID, NIH: Genomic RNA from ZIKV
Virus, MR766, NR-50085. The Asian lineage ZIKV strain:
ZIKV/H.sapiens/Brazil/PE243/2015 (abbreviated to ZIKV
PE243), was isolated from a patient from Recife, Brazil in
2015 and produced as described previously [51]; this strain
was characterized and is available at the MRC-University of
Glasgow Centre for Virus Research. ZIKV MR766 and
ZIKV PE243 were titrated on Vero cells (ATCC CCL-81)
using 96-well titration with eight replicates for each virus
dilution. Each virus was titrated with four replicates per-
formed on two occasions. The mean titre obtained for ZIKV
MR766 was 8.88107 TCID50 ml
 1 (7.89 log10, SD=0.2
Table 3. Microscopic detection of cytopathic effect observed on Vero CCL-81 cell line challenged with ZIKV
Monolayers of detector cells were incubated with 1000, 100, 10 and 1 TCID50 ZIKV MR766 and ZIKV PE243 and monitored for CPE over a period of
28 days. Data represent viral inoculations performed on 3 separate occasions (runs 1–3) for each dilution (1000, 100, 10 and 1 TCID50) of ZIKV
MR766 and PE243 on Vero CCL-81 cells. On day 14, supernatants from cultures not showing CPE were inoculated onto fresh detector cells (runs 1
and 2). Data in the table indicate the first day of CPE appearance, median and mean appearance of CPE, standard deviation and coefficient of varia-
tion. Statistical outliers were identified and removed from the analysis.
First day of CPE appearance on Vero CCL-81
Run Well ZIKV MR766 ZIKV PE243
1000 TCID50 100 TCID50 10 TCID50 1 TCID50 1000 TCID50 100 TCID50 10 TCID50 1 TCID50
1 1 3 7 7 7 3 7 7 7
2 3 7 7 7 3 7 7 7
3 3 7 7 7 3 7 7 7
4 3 7 7 7 3 7 7 7
5 3 7 14 14 3 7 7 7
6 3 7 17 17 3 7 7 7
2 7 7 7 7 7 3* 7 7 7
8 7 7 7 7 7 7 7 20
9 7 7 7 7 7 7 7 20
10 7 7 7 – 7 7 7 20
11 7 7 7 – 7 7 14 20
12 7 7 7 – 7 7 14 20
3 13 7 7 7 N/A 7 7 7 N/A
14 7 7 7 N/A 7 7 7 N/A
15 7 7 7 N/A 7 7 10 N/A
16 7 7 10 N/A 7 7 10 N/A
17 7 7 10 N/A 7 7 14 N/A
18 7 7 10 N/A 7 7 14 N/A
Median 6 7 7 7 6 7 8 14
Mean 6 7 8 8 6 7 9 14
Standard deviation 2 0 1 1 2 0 1 7
Coefficient of variation (%) 33 0 14 17 33 0 16 48
–, No CPE was visible; N/A, non-applicable.
*Statistical outlier.
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log10, n=4), and 4.8010
7 TCID50 ml
 1 (7.41 log10, SD=0.5
log10, n=4) for ZIKV PE243. The bovine parainfluenza virus
type 3 (PI3, VR-281) and measles virus (VR-24, Edmonston
strain) were obtained from ATCC. PI3 and measles viral
stocks were produced and titrated according to GMP.
In vitro adventitious virus assay platform
Detector cells (Vero ATCC C-1008, Vero ATCC CCL-81
and MRC-5 ATCC CCL 171) were seeded at 1.0105
cellsml 1 in 2ml growth medium (10% HG DMEM) in 6-
well plates. Monolayer health and confluency were exam-
ined continually post seeding. The medium was removed
from all cultures and the cells washed once with approxi-
mately 1ml/well of phosphate buffered saline (PBS, Gibco).
For negative controls inoculations, one 6-well plate per cell
type was inoculated with maintenance medium (2%
EMEM) using a volume of 0.5ml per well. Following incu-
bation at 36.5±1.5

C for 70±10min, the inoculum was
removed and the cultures were refed with 2ml per well
maintenance medium (2% EMEM). ZIKV was diluted to
titres of 2000, 200, 20 and 2 TCID50 per ml in 2% culture
medium. One 6-well plate for each cell type was inoculated
with each dilution of virus using an inoculum volume of
0.5ml per well as follows: MRC-5, Vero CCL-81 and Vero
C1008 cells were inoculated with 1000, 100, 10 and 1
TCID50 of either ZIKV MR766 or ZIKV PE243 separately.
Furthermore, MRC-5 cells were inoculated with measles
virus at 100 TCID50 and Vero cells (CCL-81 and C1008)
were inoculated with parainfluenza virus type 3 at 100
TCID50. Following incubation at 36.5±1.5

C for 70±10min,
the inoculum was removed and the cultures were refed with
2ml/well maintenance medium. Cultures were maintained
for a minimum period of 14 days, examined regularly and
fed at least once per week. On day 14, supernatant from
each well that did not exhibit CPE was inoculated onto fresh
detector cells (blind passage). A further negative control was
inoculated alongside the harvested supernatants. Following
adsorption of inocula, the cultures were incubated for a fur-
ther 14 days (a total of 28 days). During this period the cul-
tures were examined regularly for CPE and fed at least once
per week. The appearance of CPE was recorded and images
were taken where appropriate. Data represent inoculations
performed in 18 wells of detector cells seeded in 6-well
plates, on three separate occasions (runs 1–3; Tables 1–3).
Monolayers of cells in runs 1 and 2 were maintained for
28 days with a blind passage at day 14. Monolayers of cells
in run 3 were maintained for 14 days.
Statistical analysis
Statistical analysis for outliers were performed using Graph-
Pad’s Online Grubbs test (significance level 0.05, two-
tailed).
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Table 4. Summary table indicating percentage of detector cells reporting CPE at days 14 and 28 post infection
Microscopic detection of CPE observed on MRC-5 cells, Vero C1008 and Vero CCL-81 challenged with strains of ZIKV. Monolayers of detector cells
were incubated with 1000, 100, 10 and 1 TCID50 ZIKV MR766 and ZIKV PE243 and monitored for CPE over a period of 28 days. On day 14, superna-
tants from cultures with less than 100% of the wells showing CPE were inoculated onto fresh detector cells. Inoculation of detector cells with mea-
sles virus and bovine parainfluenza virus type 3 at 100 TCID50 represents system suitability controls for MRC-5 and Vero detector cell lines,
respectively.
Inoculum Virus inoculation MRC-5 Vero C1008 Vero CCL-81
TCID50 per well Infectious units (l) present* Day 14 Day 28 Day 14 Day 28 Day 14 Day 28
Negative control N/A N/A 0% 0% 0% 0% 0% 0%
ZIKV MR766 1000 690 100% 100% 100% 100% 100% 100%
100 69 100% 100% 100% 100% 100% 100%
10 6.9 61% 100% 67% 100% 94% 100%
1 0.69 33% 50% 33% 100% 44% 75%
ZIKV PE243 1000 690 67% 67% 100% 100% 100% 100%
100 69 44% 75% 100% 100% 100% 100%
10 6.9 27% 42% 67% 100% 100% 100%
1 0.69 11% 17% 56% 83% 39% 100%
Measles virus 100 69 100% 100% N/A N/A N/A N/A
PI3 100 69 N/A N/A 100% 100% 100% 100%
N/A, non-applicable.
*A TCID50 unit is the amount of virus required to result in infection of one-half of the cultures inoculated. Thus, for a virus stock at a concentration of
1 TCID50 unit/ml, the probability that a well inoculated with 1ml will be uninfected is 0.5 (and is the same as the probability that it will be infected;
i.e. P=0.5 for both). Therefore, where a volume contains 1 TCID50 unit, the number of infection units present is l=-ln (0.5) OR ln (2). Thus, 1 TCID50
unit is equivalent to ln (2) infectious units (or ~0.69 infectious units).
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